Nektar Therapeutics Cash Flow - Annual (NASDAQ:NKTR)

Add to My Stocks
$58.31 $0.94 (1.59%) NKTR stock closing price Sep 17, 2018 (Closing)

For analyzing any company like Nektar Therapeutics from an investment perspective, its important to check the cash flow statement. Financials statements like the Nektar Therapeutics income statement and Nektar Therapeutics balance sheet show that the company has profits and debt, while the cash flow statement provides details of cash flow movments. Nektar Therapeutics cash flow analysis is possible because this statement breaks down how balance sheet accounts and income statement items affect cash and cash equivalents. Nektar Therapeutics had cash and cash equivalents of $59.64M at the beginning of the year and $4.76M at year end for 2017. Nektar Therapeutics has a negative cash and cash equivalents change of $-54.87M.

View details of Nektar Therapeutics cash flows for latest & last 10 financial years
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Net Income Cash Flow
-96.69M-153.52M-81.17M-53.91M-162.01M-171.85M-133.97M-37.93M-102.51M-34.33M
Depreciation Depletion Amortization Cash-Flow14.74M15.35M12.85M12.92M14.27M14.5M14.95M16.55M14.88M22.48M
Net Increase (Decrease) in Assets Liabilities-37.61M7.93M-34.7M-116.42M90.58M1.6M-14.95M-64.65M117.7M-26.79M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net39.15M13.21M29.94M15.4M18.62M25.98M20.24M30.17M9.66M-107.14M
Net Cash from (used by) Operating Activities
-80.41M-117.02M-73.08M-142M-38.52M-129.75M-113.74M-55.87M39.73M-145.78M
Increase (Decrease) in Prop Plant And Equipment-9.67M-6.39M-11.19M-9.97M-4.09M-10.58M-9.72M-31.45M-20.7M-18.85M
Acquisition Disposition of Subsidiaires---------4.44M114.83M
Increase (Decrease) in Investments-19.13M-76M-28.14M-27.59M54M148.6M-102.23M48.16M-123.89M178.67M
Other Cash Inflow (Outflow) from Investment Activities--25M---25M----
Net Cash from (used by) Investment Activities
-28.8M-82.4M-14.33M-37.57M49.9M113.02M-111.95M16.71M-149.03M274.65M
Issuance (Purchase) of Equity Shares59.52M209.56M32.2M163.52M8.2M4.11M224.31M8.89M4.82M-
Issuance (Repayment) of Debt Securities-5.13M-5.94M98.57M-3.53M-2.99M-96.9M-1.97M-1.35M-1.28M-50.12M
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities----7M-3M119.58M----
Net Cash from (used by) Financing Activities
54.39M203.61M130.78M152.98M2.21M26.8M222.33M7.53M3.53M-49.74M
Effect of Exchange Rate Changes on Cash-0.04M-0.12M-0.15M-0.1M----0.21M-0.22M-
Net Change in Cash & Cash Equivalents
-54.87M4.07M43.2M-26.7M13.63M10.12M-2.44M-31.84M-105.98M79.29M
Cash & Equivalents at Beginning of Year59.64M55.57M12.36M39.06M25.43M15.31M17.75M49.59M155.58M76.29M
Cash & Equivalents at Year End4.76M59.64M55.57M12.36M39.06M25.43M15.31M17.75M49.59M155.58M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

The statement of cash flows comprises of cash flow from financing, cash flow from operations and cash flow from investing activities. All the three can have an impact on the stock price. The Nektar Therapeutics stock price history and Nektar Therapeutics stock comparison chart inevitably reflect its cash flow situation.

  • Nektar Therapeutics had a Net Change in Cash and Cash Equivalents of $-54.87M for the latest year 2017. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the Nektar Therapeutics stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • The cash generated from the core business or operations was a negative at $-80.41M for Nektar Therapeutics in the latest 2017. For an internet company, this would include all those activities which are involved in eventually selling advertisement space on its website or any online service.
  • Cash Flow from investment activities: Nektar Therapeutics used $-28.8M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Cash Flow from financing activities: Financing activities include the cash that comes into a company in the form of loans or interest earned or shareholders money, as well as the cash that goes out. Nektar Therapeutics earned $54.39M from financing activities, in the form of repayment of loans or interest paid, dividend pay-out to shareholders etc.

Key Financial Ratios For Nektar Therapeutics Cash Flow

FCF margin
0.88